Rodger Alan Liddle, MD

Professor of Medicine
Faculty Network Member of the Duke Institute for Brain Sciences
Member of the Duke Cancer Institute
Campus mail 1033A GSRB-1 Bldg, Durham, NC 27710
Phone (919) 681-6380
Email address rodger.liddle@duke.edu

Our laboratory has two major research interests:

Enteroendocrine Cell Biology

Enteroendocrine cells (EECs) are sensory cells of the gut that send signals throughout the body.  They have the ability to sense food and nutrients in the lumen of the intestine and secrete hormones into the blood.  Our laboratory has had a longstanding interest in two types of EECs that regulate satiety and signal the brain to stop eating.   Cholecystokinin (CCK) is secreted from EECs of the upper small intestine and regulates the ingestion and digestion of food through effects on the stomach, gallbladder, pancreas and brain.  Peptide YY (PYY) is secreted from EECs of the small intestine and colon and regulates satiety.  We recently demonstrated that CCK and PYY cells not only secrete hormones but are directly connected to nerves through unique cellular processes called ‘neuropods’.  Our laboratory is devoted to understanding EECs signaling and its role in disease.

Pancreatitis

Pancreatitis is an inflammatory disease of the pancreas compounded by intrapancreaatic activation of digestive enzymes.  Our laboratory is studying the influence of nerves on the development of pancreatitis. Neurogenic inflammation results from the release of bioactive substances from sensory neurons in the pancreas causing vasodilatation, edema, and inflammatory cell infiltration producing tissue necrosis. Our goal is to identify the agents that activate sensory neurons, characterize the receptors on sensory nerves that mediate these actions, and determine the effects of neural stimulation on pancreatic injury with the long-term objective of developing strategies to reduce neurogenic inflammation to treat pancreatitis. 

Visit our lab page.

Education and Training

  • Gastroenterology Fellowship, Gastroenterology, University of California - San Francisco, 1981 - 1984
  • Residency, Generalinternal Medicine, University of California - San Francisco, 1979 - 1981
  • Internship, General Internal Medicine, University of California - San Francisco, 1978 - 1979
  • M.D., Vanderbilt University, 1978
  • B.S., University of Utah, 1972

Publications

Liddle, Rodger A., Martin Freeman, Diane M. Simeone, Ashok K. Saluja, Carlos Fernandez-Del Castillo, Anirban Maitra, Stephen J. Pandol, and Vay Liang W. Go. “Minutes of the business meeting of the American Pancreatic Association, Friday, November 2, 2012, Miami, Florida..” Pancreas 42, no. 8 (November 2013): 1333–34. https://doi.org/10.1097/MPA.0b013e3182a99936.

PMID
24152959
Full Text

Chandra, Rashmi, Yu Wang, Rafiq A. Shahid, Steven R. Vigna, Neil J. Freedman, and Rodger A. Liddle. “Immunoglobulin-like domain containing receptor 1 mediates fat-stimulated cholecystokinin secretion..” J Clin Invest 123, no. 8 (August 2013): 3343–52. https://doi.org/10.1172/JCI68587.

PMID
23863714
Full Text

Shahid, Rafiq A., Steven R. Vigna, and Rodger A. Liddle. “Bile Acid-Induced Acute Pancreatitis Is Mediated by Acinar Cell Leukotriene B-4 Secretion.” In Gastroenterology, 144:S320–S320. W B SAUNDERS CO-ELSEVIER INC, 2013.

Scholars@Duke

Chandra, Rashmi, Yu Wang, Rafiq A. Shahid, Steven R. Vigna, Neil J. Freedman, and Rodger A. Liddle. “Immunoglobulin-Like Domain Containing Receptor Mediates Fat-Stimulated Cholecystokinin Secretion.” In Gastroenterology, 144:S8–S8. W B SAUNDERS CO-ELSEVIER INC, 2013.

Scholars@Duke

Sundaresan, Sinju, Rafiq Shahid, Terrence E. Riehl, Rashmi Chandra, Fatiha Nassir, William F. Stenson, Rodger A. Liddle, and Nada A. Abumrad. “CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin..” Faseb J 27, no. 3 (March 2013): 1191–1202. https://doi.org/10.1096/fj.12-217703.

PMID
23233532
Full Text

Shah, Tilak Upendra, Rodger Liddle, M Stanley Branch, Paul Jowell, Jorge Obando, and Martin Poleski. “Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial..” Jop 13, no. 5 (September 10, 2012): 514–18. https://doi.org/10.6092/1590-8577/855.

PMID
22964958
Full Text

Pages